Expectant management of localized prostate cancer

Urology. 2003 Nov;62(5):793-9. doi: 10.1016/s0090-4295(03)00653-8.

Authors

Masood A Khan¹, Alan W Partin, H Ballentine Carter

Affiliation

¹ James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

PMID: 14624896
DOI: 10.1016/s0090-4295(03)00653-8

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adenocarcinoma / blood
Adenocarcinoma / epidemiology
Adenocarcinoma / pathology
Adenocarcinoma / therapy*
Aged
Aged, 80 and over
Biomarkers, Tumor / blood
Cell Differentiation
Disease Progression
Follow-Up Studies
Humans
Life Expectancy
Male
Mass Screening
Middle Aged
Neoplasm Invasiveness
Palliative Care
Patient Selection
Prostate-Specific Antigen / blood
Prostatic Neoplasms / blood
Prostatic Neoplasms / epidemiology
Prostatic Neoplasms / pathology
Prostatic Neoplasms / therapy*
Survival Analysis
Unnecessary Procedures

Substances

Biomarkers, Tumor
Prostate-Specific Antigen